A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, we are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. In 2026, we expect to progress our ENTR-601-44 and ENTR-601-45 clinical trials, an EU filing for the ENTR-601-50 clinical trial, and regulatory submissions for ENTR-601-51. In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated (“Vertex”) continues to progress, with dosing completion anticipated in mid-2026. We anticipate reporting on the results of two cohorts of patient data from our ENTR-601-44 program, and one from our ENTR-601-45 program during 2026.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 0 | - | 211M | 129M | 0 |
| Net Income | -144M | -144M | 66M | -6.7M | -95M |
| EPS | $-3.47 | $-3.47 | $1.68 | $-0.20 | $-3.02 |
| Free Cash Flow | -130M | -130M | -45M | 134M | -97M |
| ROIC | -57.8% | -47.0% | 20.5% | -2.8% | -44.5% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.23 | 0.23 | 0.94 | 0.19 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -158M | -158M | 47M | -3.2M | -97M |
| Operating Margin | 0.0% | - | 22.3% | -2.5% | - |
| ROE | -47.0% | -39.1% | 15.3% | -2.8% | -44.5% |
| Shares Outstanding | 41M | 41M | 39M | 33M | 31M |
| Metric | 2022 | 2023 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0 | 129M | 211M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | 67M | 100M | 125M | 142M | 142M |
| SG&A | 31M | 32M | 38M | 41M | 41M |
| EBIT | -97M | -3.2M | 47M | -158M | -158M |
| Op. Margin | N/A | -2.5% | 22.3% | N/A | 0.0% |
| Net Income | -95M | -6.7M | 66M | -144M | -144M |
| Net Margin | N/A | -5.2% | 31.1% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -44.5% | -2.8% | 20.5% | -47.0% | -57.8% |
| ROE | -44.5% | -2.8% | 15.3% | -39.1% | -47.0% |
| ROA | -37.5% | -1.4% | 12.5% | -31.8% | -38.1% |
| Cash Flow | |||||
| Op. Cash Flow | -94M | 140M | -42M | -129M | -129M |
| Free Cash Flow | -97M | 134M | -45M | -130M | -130M |
| Owner Earnings | -106M | 124M | -63M | -152M | -152M |
| CapEx | 2.9M | 5.6M | 3.2M | 1.0M | 1.0M |
| Maint. CapEx | 1.9M | 2.8M | 3.8M | 4.1M | 4.1M |
| Growth CapEx | 992K | 2.8M | 0 | 0 | 0 |
| D&A | 1.9M | 2.8M | 3.8M | 4.1M | 4.1M |
| CapEx/OCF | N/A | 4.0% | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 9.9M | 13M | 18M | 20M | 20M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -90M |
| Cash & Equiv. | 45M | 68M | 101M | 90M | 90M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.19 | 0.94 | 0.23 | 0.23 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A |
| Equity | 213M | 242M | 429M | 306M | 306M |
| Total Assets | 252M | 469M | 526M | 377M | 377M |
| Total Liabilities | 40M | 227M | 98M | 71M | 71M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -188M | -195M | -129M | -273M | -273M |
| Working Capital | 188M | 211M | 401M | 282M | 282M |
| Current Assets | 210M | 370M | 440M | 306M | 306M |
| Current Liabilities | 22M | 159M | 39M | 24M | 24M |
| Per Share Data | |||||
| EPS | -3.02 | -0.20 | 1.68 | -3.47 | -3.47 |
| Owner EPS | -3.37 | 3.71 | -1.62 | -3.67 | -3.67 |
| Book Value | 6.78 | 7.25 | 10.97 | 7.39 | 7.39 |
| Cash Flow/Share | -2.99 | 4.18 | -1.06 | -3.10 | -3.37 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 31.3M | 33.4M | 39.1M | 41.4M | 41.4M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | 10.4 | N/A | -4.0 |
| P/FCF | N/A | 4.1 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 2.0 | 2.3 | 1.6 | 1.4 | 1.9 |
| Price/Sales | N/A | 3.7 | 2.9 | N/A | N/A |
| FCF Yield | -22.8% | 24.5% | -6.6% | -30.0% | -22.5% |
| Market Cap | 424M | 549M | 680M | 431M | 575M |
| Avg. Price | 12.23 | 14.42 | 15.56 | 8.69 | 13.89 |
| Year-End Price | 13.54 | 16.41 | 17.41 | 10.41 | 13.89 |
Entrada Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -0.1%.
Entrada Therapeutics, Inc. (TRDA) has a 5-year average return on invested capital (ROIC) of -18.4%. This is below average and may indicate limited pricing power.
Entrada Therapeutics, Inc. (TRDA) has a market capitalization of $575M. It is classified as a small-cap stock.
Entrada Therapeutics, Inc. (TRDA) does not currently pay a regular dividend.
Entrada Therapeutics, Inc. (TRDA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Entrada Therapeutics, Inc. (TRDA) generated $-130 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Entrada Therapeutics, Inc. (TRDA) has a debt-to-equity ratio of 0.23. This indicates a conservatively financed balance sheet.
Entrada Therapeutics, Inc. (TRDA) reported earnings per share (EPS) of $-3.47 in its most recent fiscal year.
Entrada Therapeutics, Inc. (TRDA) has a return on equity (ROE) of -39.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Entrada Therapeutics, Inc. (TRDA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Entrada Therapeutics, Inc. (TRDA) has a book value per share of $7.39, based on its most recent annual SEC filing.